Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Figure 2

Cabozantinib alters the immune-cell repertoire of C57BL/6 mice. (A) Serum concentration of cabozantinib in mice fed control diet or diet containing cabozantinib for 10 days (n =5/group). Dashed line indicates the plasma concentration achieved at the maximum tolerated dose in a phase 1 human clinical trial. (B) Number of viable cells/spleen in mice fed control diet or cabozantinib diet for 35 days. The frequency of (C) CD4+ T cells (CD3+ CD4+), (D) CD8+ T cells (CD3+ CD8+), (E) Tregs (CD3+CD4+CD25+FoxP3+), and (F) MDSCs (CD11b+GR-1+) in spleens of mice fed control diet or cabozantinib diet for 35 days was determined by flow cytometry. Error bars indicate mean ± SEM. Statistical analyses were done by Student's t test. * = P <0.05. Data are representative of 4 independent experiments.

Back to article page